Tiziana Life Sciences
  • Our Company
    • Our Company
    • About us
    • Our Team
  • Technology
  • Pipeline
    • Intranasal Foralumab
      • Secondary Progressive Multiple Sclerosis
      • Alzheimer’s Disease
      • Other Indications
    • Anti IL-6R (TZLS-501)
  • Investors, News & Media
    • News
    • Media
    • Publications
    • Investors
  • Contact
Select Page
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

by Paul | 27 February 2025 | News

Traumatic brain injury is a leading cause of death and disability Currently, there is no treatment to prevent the long-term effects of traumatic brain injury Findings could translate into treating intracerebral hemorrhage or stroke NEW YORK, February 27, 2025 –...

Recent Posts

  • Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
  • Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
  • Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
  • Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
  • Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Recent Comments

No comments to show.

Tiziana Life Sciences, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda  |  info@tizianalifesciences.com   |  +44 (0) 207 495 2379

  • Follow
  • Follow

© Tiziana Life Sciences 2026  |   Legal  |  Privacy Policy

NASDAQ: TLSA